NEW YORK and PETACH TIKVAH, Israel, June 25, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call tomorrow, June 26 ^th at 08:30am Eastern Time, to announce its policy in regards to the "Right To Try" legislation.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Media:
Drew Levinson
LifeSci Public Relations
Phone 917-797-0388
drew@lifescipublicrelations.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-to-host-tomorrow-a-conference-call-to-announce-its-right-to-try-policy-300671492.html

SOURCE BrainStorm Cell Therapeutics Inc.